24-Aug-2020 - Berliner Institut für Gesundheitsforschung (BIH)

A potential new target for immunotherapies in cancer

Compounds that inhibit metabolic enzyme IL4I1 could open up new opportunities for cancer therapy

The metabolic enzyme IL4I1 (interleukin-4-induced-1) promotes the spread of tumor cells and suppresses the immune system. This was discovered by scientists from the Berlin Institute of Health (BIH) together with colleagues from the German Cancer Research Center (DKFZ) in Heidelberg. The enzyme is produced to a greater extent in tumors and activates the dioxin receptor. Compounds that inhibit IL4I1 could open up new opportunities for cancer therapy in the future.

Immunotherapies activate the body's own immune response against tumors and are currently revolutionizing cancer therapy. Despite some astonishing individual successes only a small number of patients benefit from current immunotherapies. The teams led by Christiane Opitz and Martina Seiffert, both at the DKFZ, and Saskia Trump, from the Berlin Institute of Health (BIH), investigated the molecular mechanisms that tumors use to escape their destruction by the immune system.

The aryl hydrocarbon receptor (AHR) is also known as the dioxin receptor because it mediates the toxic effect of dioxins. However, not only toxins, but also the body's own metabolites can activate the receptor. One example are degradation products of the amino acid tryptophan, which we take in with our food as a building block of proteins. Tumors use these metabolic products to their advantage by promoting the mobility of tumor cells and weakening the immune response against tumors. "Currently there is insufficient knowledge on how these degradation products are produced," explains Ahmed Sadik from the German Cancer Research Center (DKFZ). In order to change this, he and his colleagues investigated in more than 32 different tumor types which tryptophan-degrading enzymes are associated with an activation of the dioxin receptor.

One molecule in particular caught the scientists' eye: the enzyme IL4I1. No other tryptophan-catabolizing enzyme associated with AHR activity as frequently as IL4I1. "The metabolites formed by IL4I1 bind to the dioxin receptor and activate it, which leads to the suppression of immune cells and can impair the body’s defense against the tumor ," explains Saskia Trump, who heads the Epigenetics research group of the Molecular Epidemiology Unit at the Berlin Institute of Health. In patients with gliomas, malignant brain tumors, the survival probability decreased when the enzyme IL4I1 was present in higher concentrations in these tumors.

A mouse model for chronic lymphocytic leukemia (CLL), a type of blood cancer, demonstrated that the enzyme promotes cancer through its effects on the immune system. “In animals that do not produce IL4I1 in the tumor micro-environment due to genetic changes, the immune system is significantly more successful in preventing the cancer progression," explains Martina Seiffert, DKFZ.

"IL4I1 has great potential as a drug target. So far, substances that inhibit tryptophan metabolism have failed in clinical studies because the tumors did not respond to them. This might be due to the fact that the role of IL4I1 has been disregarded and it has not yet been tested as a target molecule," said Christiane Opitz, highlighting the potential clinical application of the study results.

Facts, background information, dossiers
More about Berliner Institut für Gesundheitsforschung (BIh)
  • News

    The human helpers of SARS-CoV-2

    Like all viruses, the novel coronavirus is dependent on help from the human host cell. Proteins are the functional units of the cell and enable the virus to enter the host cell or help the virus to replicate. Scientists from the Berlin Institute of Health (BIH), Charité – Universitätsmedizi ... more

    When does it make sense to develop a new therapeutic agent?

    Scientists from the Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin, along with colleagues from the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME-TMP) in Frankfurt am Main and PAASP GmbH in Heidelberg, have compiled a catalogue of recommendati ... more

    New software detects disease-causing gene mutations

    A serious illness is often the result of a single genetic defect. But given that two healthy people already have around three million differences in their genetic make-up, it is no easy task to pick out the one disease-causing deviation from the many harmless gene variants. Scientists at th ... more

More about Deutsches Krebsforschungszentrum
  • News

    Engineering T cells for cancer therapy efficiently and safely

    Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the Ge ... more

    New single-cell analysis of leucemic stem cells

    A new method allows stem cells and cancer stem cells to be studied at the single cell level and the resulting cell clones to be traced directly. The method was developed by scientists from the Stem Cell Institute HI-STEM, the German Cancer Research Center (DKFZ), the European Molecular Biol ... more

    Induced pluripotent stem cells reveal causes of disease

    Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied ... more

  • Research Institutes

    Deutsches Krebsforschungszentrum - DKFZ

    Cancer, with over 450,000 new cases diagnosed and 270,000 deaths each year, is one of the most dreaded diseases and the second most frequent cause of death in Germany. More than almost any other disease, cancer poses tremendous challenges for research and clinical practice. Practically ever ... more